vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $51.3333.

A number of analysts recently issued reports on VTVT shares. Cowen assumed coverage on vTv Therapeutics in a research note on Monday. They set a “buy” rating on the stock. TD Cowen started coverage on shares of vTv Therapeutics in a research note on Monday. They issued a “buy” rating and a $67.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Wall Street Zen raised vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Finally, BTIG Research initiated coverage on vTv Therapeutics in a research note on Wednesday, November 19th. They issued a “buy” rating and a $40.00 target price on the stock.

Hedge Funds Weigh In On vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP lifted its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 148,314 shares of the biotechnology company’s stock after acquiring an additional 51,000 shares during the period. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Trading Up 2.2%

Shares of NASDAQ VTVT opened at $40.87 on Monday. The stock has a fifty day simple moving average of $30.51 and a two-hundred day simple moving average of $22.39. vTv Therapeutics has a 1-year low of $13.20 and a 1-year high of $41.49. The firm has a market cap of $161.03 million, a price-to-earnings ratio of -12.55 and a beta of 0.48.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.